series-c-plus
Stage
2
Investors
About
Synthekine develops engineered cytokine therapeutics, including cytokine partial agonists and surrogate cytokine agonists, targeting cancer and autoimmune, inflammatory, and metabolic diseases with clinical programs such as STK-012 and SYNERGY-101 in non-small cell lung cancer.
Explore Synthekine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.